New Patent Granted for Prostate Cancer Drug Masitinib
治療前列腺癌藥物 Masitinib 獲頒新專利
更新於: 2026年6月18日 上午02:01
A significant breakthrough in oncology has emerged as AB Science SA secured a U.S. patent for its lead compound, masitinib, targeting metastatic castrate-resistant prostate cancer (mCRPC).
腫瘤學領域出現重大突破，AB Science SA 公司針對其領先化合物「馬賽替尼」(masitinib) 取得了美國專利，該藥物旨在治療轉移性去勢抗性前列腺癌 (mCRPC)。
This patent, valid until 2042, marks a pivotal moment for a field that has seen no new combination therapies for nearly two decades.
此項專利有效期限至 2042 年，對於已近二十年未見新式聯合療法的領域而言，標誌著一個關鍵時刻。
Masitinib works as a protein kinase inhibitor, intended to be used alongside docetaxel.
馬賽替尼是一種蛋白激酶抑制劑，預計與多西他賽 (docetaxel) 合併使用。
What sets this treatment apart is its commitment to precision medicine.
此療法與眾不同之處在於對精準醫療的承諾。
Clinical data from the Phase 3 AB12003 study showed a 21% reduction in disease progression risk for patients with ALP levels at or below 250 IU/L.
第三期臨床試驗 AB12003 的數據顯示，對於 ALP 數值不高於 250 IU/L 的患者，其疾病惡化風險降低了 21%。
The long-term patent protection provides the stability needed for large-scale clinical trials, signaling a hopeful shift toward personalized, biomarker-driven cancer care.
長期的專利保護提供了進行大規模臨床試驗所需的穩定性，標誌著醫療界正朝向個人化、以生物標記為導向的癌症護理邁出充滿希望的一步。
